Literature DB >> 18539662

Metal-on-metal hip resurfacing in developmental dysplasia: a case-control study.

C W McBryde1, E Shears, J N O'Hara, P B Pynsent.   

Abstract

Metal-on-metal hip resurfacing was performed for developmental dysplasia in 96 hips in 85 patients, 78 in women and 18 in men, with a mean age at the time of surgery of 43 years (14 to 65). These cases were matched for age, gender, operating surgeon and date of operation with a group of patients with primary osteoarthritis who had been treated by resurfacing, to provide a control group of 96 hips (93 patients). A clinical and radiological follow-up study was performed. The dysplasia group were followed for a mean of 4.4 years (2.0 to 8.5) and the osteoarthritis group for a mean of 4.5 years (2.2 to 9.4). Of the dysplasia cases, 17 (18%) were classified as Crowe grade III or IV. There were five (5.2%) revisions in the dysplasia group and none in the osteoarthritic patients. Four of the failures were due to acetabular loosening and the other sustained a fracture of the neck of femur. There was a significant difference in survival between the two groups (p = 0.02). The five-year survival was 96.7% (95% confidence interval 90.0 to 100) for the dysplasia group and 100% (95% confidence interval 100 to 100) for the osteoarthritic group. There was no significant difference in the median Oxford hip score between the two groups at any time during the study. The medium-term results of metal-on-metal hip resurfacing in all grades of developmental dysplasia are encouraging, although they are significantly worse than in a group of matched patients with osteoarthritis treated in the same manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539662     DOI: 10.1302/0301-620X.90B6.20026

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  9 in total

1.  Revision rate of Birmingham Hip Resurfacing arthroplasty: comparison of published literature and arthroplasty register data.

Authors:  Reinhard Schuh; Daniel Neumann; Rauend Rauf; Jochen Hofstaetter; Nikolaus Boehler; Gerold Labek
Journal:  Int Orthop       Date:  2012-02-22       Impact factor: 3.075

2.  Prevalence of dysplasia as the source of worse outcome in young female patients after hip resurfacing arthroplasty.

Authors:  Thomas P Gross; Fei Liu
Journal:  Int Orthop       Date:  2011-06-07       Impact factor: 3.075

3.  Total hip replacement with an uncemented Wagner cone stem for patients with congenital hip dysplasia.

Authors:  Raúl Torres Claramunt; Fernando Marqués; Alfonso León; Gemma Vilà; Carlos Mestre; Lluís Puig Verdié
Journal:  Int Orthop       Date:  2011-02-12       Impact factor: 3.075

4.  Hip resurfacing for rheumatoid arthritis: independent assessment of 11-year results from an international register.

Authors:  Tajeshwar S Aulakh; Jan H Kuiper; Josh Dixey; James B Richardson
Journal:  Int Orthop       Date:  2010-05-25       Impact factor: 3.075

5.  Hip resurfacing data from national joint registries: what do they tell us? What do they not tell us?

Authors:  Kristoff Corten; Steven J MacDonald
Journal:  Clin Orthop Relat Res       Date:  2010-02       Impact factor: 4.176

6.  Survival and functional outcome of the Birmingham Hip Resurfacing system in patients aged 65 and older at up to ten years of follow-up.

Authors:  Regis Pailhe; Gulraj S Matharu; Akash Sharma; Paul B Pynsent; Ronan B Treacy
Journal:  Int Orthop       Date:  2013-12-28       Impact factor: 3.075

7.  Hip resurfacing in patients under thirty years old: an attractive option for young and active patients.

Authors:  Nicolas Krantz; Bruno Miletic; Henri Migaud; Julien Girard
Journal:  Int Orthop       Date:  2012-05-11       Impact factor: 3.075

8.  Early catastrophic failure of Birmingham acetabular dysplasia cup in revision arthroplasty: a case report.

Authors:  Manjunath Ramappa; Andrew Port
Journal:  Cases J       Date:  2009-07-30

9.  Reducing the failure rate of hip resurfacing in dysplasia patients: a retrospective analysis of 363 cases.

Authors:  Melissa D Gaillard; Thomas P Gross
Journal:  BMC Musculoskelet Disord       Date:  2016-06-07       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.